Cargando…
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
BACKGROUND: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulator...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984796/ https://www.ncbi.nlm.nih.gov/pubmed/27031851 http://dx.doi.org/10.1038/bjc.2016.42 |
_version_ | 1782447990914416640 |
---|---|
author | Loskog, Angelica Maleka, Aglaia Mangsbo, Sara Svensson, Emma Lundberg, Christina Nilsson, Anders Krause, Johan Agnarsdóttir, Margrét Sundin, Anders Ahlström, Håkan Tötterman, Thomas H Ullenhag, Gustav |
author_facet | Loskog, Angelica Maleka, Aglaia Mangsbo, Sara Svensson, Emma Lundberg, Christina Nilsson, Anders Krause, Johan Agnarsdóttir, Margrét Sundin, Anders Ahlström, Håkan Tötterman, Thomas H Ullenhag, Gustav |
author_sort | Loskog, Angelica |
collection | PubMed |
description | BACKGROUND: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulatory gene therapy was evaluated in patients with MM. METHODS: AdCD40L is an adenovirus carrying the gene for CD40 ligand. Patients that failed standard treatments were enrolled. Six patients received four weekly intratumoral AdCD40L injections. Next, nine patients received low-dose cyclophosphamide conditioning before the first and fourth AdCD40L injection. The blood samples were collected at multiple time points for chemistry, haematology and immunology evaluations. Radiology was performed at enrolment and repeated twice after the treatment. RESULTS: AdCD40L was safe with mild transient reactions. No objective responses were recorded by MRI, however, local and distant responses were seen on FDG-PET. The overall survival at 6 months was significantly better when cyclophosphamide was added to AdCD40L. The patients with the best survival developed the highest levels of activated T cells and experienced a pronounced decrease of intratumoral IL8. CONCLUSIONS: AdCD40L therapy for MM was well tolerated. Local and distant responses along with better survival in the low-dose cyclophosphamide group are encouraging. |
format | Online Article Text |
id | pubmed-4984796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49847962017-04-12 Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients Loskog, Angelica Maleka, Aglaia Mangsbo, Sara Svensson, Emma Lundberg, Christina Nilsson, Anders Krause, Johan Agnarsdóttir, Margrét Sundin, Anders Ahlström, Håkan Tötterman, Thomas H Ullenhag, Gustav Br J Cancer Clinical Study BACKGROUND: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulatory gene therapy was evaluated in patients with MM. METHODS: AdCD40L is an adenovirus carrying the gene for CD40 ligand. Patients that failed standard treatments were enrolled. Six patients received four weekly intratumoral AdCD40L injections. Next, nine patients received low-dose cyclophosphamide conditioning before the first and fourth AdCD40L injection. The blood samples were collected at multiple time points for chemistry, haematology and immunology evaluations. Radiology was performed at enrolment and repeated twice after the treatment. RESULTS: AdCD40L was safe with mild transient reactions. No objective responses were recorded by MRI, however, local and distant responses were seen on FDG-PET. The overall survival at 6 months was significantly better when cyclophosphamide was added to AdCD40L. The patients with the best survival developed the highest levels of activated T cells and experienced a pronounced decrease of intratumoral IL8. CONCLUSIONS: AdCD40L therapy for MM was well tolerated. Local and distant responses along with better survival in the low-dose cyclophosphamide group are encouraging. Nature Publishing Group 2016-04-12 2016-03-31 /pmc/articles/PMC4984796/ /pubmed/27031851 http://dx.doi.org/10.1038/bjc.2016.42 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Clinical Study Loskog, Angelica Maleka, Aglaia Mangsbo, Sara Svensson, Emma Lundberg, Christina Nilsson, Anders Krause, Johan Agnarsdóttir, Margrét Sundin, Anders Ahlström, Håkan Tötterman, Thomas H Ullenhag, Gustav Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
title | Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
title_full | Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
title_fullStr | Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
title_full_unstemmed | Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
title_short | Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
title_sort | immunostimulatory adcd40l gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984796/ https://www.ncbi.nlm.nih.gov/pubmed/27031851 http://dx.doi.org/10.1038/bjc.2016.42 |
work_keys_str_mv | AT loskogangelica immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT malekaaglaia immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT mangsbosara immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT svenssonemma immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT lundbergchristina immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT nilssonanders immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT krausejohan immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT agnarsdottirmargret immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT sundinanders immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT ahlstromhakan immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT tottermanthomash immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients AT ullenhaggustav immunostimulatoryadcd40lgenetherapycombinedwithlowdosecyclophosphamideinmetastaticmelanomapatients |